Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Antibody-drug conjugates offer hope for the treatment of hormone resistant prostate cancer

17 Aug 04

DailyUpdates 17th August, 2004: Researchers from Protein Design Laboratories report that an antibody-drug conjugate that links the chemotherapeutic agent Auristatin to a prostate cancer specific antibody, anti-TMEFF2 mAb, via a cathepsin B-sensitive linker prevents tumor growth in a murine model of prostate cancer.
LeadDiscovery

Proteolytic beta amyloid light chain antibody fragments offer promise as future treatments of Alzheimer’s disease.

17 Aug 04

DailyUpdates 18th August, 2004: Researchers from at Arizona State University have demonstrated that beta amyloid light chain proteolytic antibody fragments can cleave beta-amyloid, altering the aggregation and neutralizing the cytotoxic effects of this peptide.
LeadDiscovery

Time to Prioritize Neglected Diseases?

17 Aug 04

In recent years a greater effort has been made by international healthcare organizations and governments to tackle diseases that have their heaviest impact in the developing world. Many of these diseases have been called ‘neglected diseases’ as few new drugs have been launched to tackle them during the last 20 years.
Dr Faiz Kermani

New rhinitis therapy should help patients to breathe easy

13 Aug 04

Rigel's new intranasal inhibitor R112 could offer a useful alternative therapy for patients suffering from allergic rhinitis, as Datamonitor's Shaun Falkingbridge explains. Bolstered by supportive recent trial results, Rigel can now go on to seek partner firms to realize full commercialization of the drug...
Datamonitor

US online pharmacies can attract consumers from cross-border discounters

12 Aug 04

The trade in discounted prescription drugs between Canada and the US has elicited considerable controversy on both sides of the border. Yet recent figures show that sales of drugs via Canadian pharmacies have not been as great as some had predicted. However, as Datamonitor's David Deon explains, pharmaceutical companies could go further by driving the expansion of online prescribing in the US...
Datamonitor

Lipoxin A4 (LXA4) mimics shown reduce inflammation by inhibiting the p38-MAPK pathway-further proof of concept for LXA4 analogues in preclinical development

11 Aug 04

The p38-MAPK pathway has long been targeted by the pharmaceutical industry in an attempt to identify new anti-inflammatory agents. The development of p38-MAPK inhibitors has however been impeded by adverse effects. Boston University researchers have now demonstrated that the lipoxin A4 (LXA4) mimic, ATLa inhibits the p38-MAPK cascade explaining in part its anti-inflammatory efficacy and offering a new approach to this promising pharmaceutical target. Although ATLa has a poor pharmacokinetic p
LeadDiscovery

France feels out the future of biotech

10 Aug 04

After a period of exceptional performance due to a steady flow of investment in the sector, the biotechnology industry in France was hard hit by the global economic depression of 2002. The government must support the French Biotechnology sector to allow it to assert its position at an international level and to enable consolidation of new start-up companies.
Yohan Vezinhet

Tuberculosis – the return of a killer

06 Aug 04

Although around 2 million people died as a result of tuberculosis (TB) in 2002 international efforts to tackle its spread are being hampered by complacency and underinvestment.
Dr Faiz Kermani

Big bucks battling super bugs?

03 Aug 04

Bacterial skin diseases like gangrene can now expect an onslaught of new specialist medications. However, skin infections make up a relatively small proportion of the $20.4 billion annual global antibacterial market, which, says Datamonitor's Amber Gibson, raises questions about why such conditions are the current focus of so much antibacterial product development...
Datamonitor

Generics companies step into the unknown…

29 Jul 04

Although generics have an important role to play in healthcare there remains a high demand for innovative medicines. Consequently, a number of generics companies have become interested in extending their R&D programmes to make their products appear more than simple copies of their branded competitors.
Dr Faiz Kermani

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.